Tumor vaccines

LaTemple, D.C., Abrams, J.T., Zhang, S.Y. et al. (1999) Increased immunogenicity of tumor vaccines complexed with anti-Gal studies in knockout mice for a 1,3galactosyltransferase. Cancer Research, 59 (14), 3417-3423. 

Yoshikawa T, Okada N, Oda A et al (2008) Development of amphiphilic y-PGA-nanoparticle based tumor vaccine potential of the nanoparticulate cytosolic protein delivery carrier. Biochem Biophys Res Commun 366 408 -13... 

CeUular Therapies. Since 1984 CBER has reviewed close to 300 somatic cell therapy protocols. Examples of the specific categories include manipulation, selection, mobilization, tumor vaccines and other. 

Tumor Vaccines. Autologous or allogenic tumor cells which are administered as vaccine (e.g., tumor cell lines tumor cell lysates primary explant). This group also includes autologous antigen presenting cells pulsed with tumor specific peptides or tumor cell lysates. 

Other. Products that do not specifically fit under the above (e.g., tumor vaccines in which cells are cultured or transduced ex vivo with a vector). 

Zatloukal K, et al. Somatic gene therapy for cancers the utility of transfer infection in generating tumor vaccines. Gene 1993 135 199-207. 

Like patients with breast carcinoma, those with ovarian cancer may benefit from treatment with Herceptin in combination with chemotherapeutic drugs. Herceptin treatment is effective, in both early and advanced stages of ovarian cancer (when the majority of tumor cells express HER-2 protein), for eliminating the potentially more malignant HER-2-positive tumor cells. The effectiveness of Herceptin is based on the affinity of this monoclonal antibody for the extracellular domain of HER-2, which is common as ovarian carcinomas progress. However, a tumor vaccine inducing antibody and/or T-cell immunity to HER-2 epitopes will ultimately provide the most effective means to prevent the emergence of HER-2-positive cells. 

Mahvi, D.M., Burkholder, J.K., Turner, J., Culp, J., Malter, J.S., Sondel, P.M. and Yang, N.S. (1996) Particle-mediated gene transfer of granulocyte macrophage-colony stimulating factor cDNA to tumor cells—implications for a clinically relevant tumor vaccine. Hum. Gene Ther., 7, 1535-1543. 

Mahnke YD, Schirrmacher V. Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response. Inti I Oncol 2004 24 1427-34. 

Some workers have proposed use of anti-idiotypic antibodies as type of tumor vaccine. In this approach, a MoAb is prepared against a given tumor antigen. Rather than using it for immunotherapy directly, it is... 

Conjugated monoclonal antibodies can be used as carriers of toxic therapy, such as radionuclides, (e.g., yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab), cytotoxic drugs, or cell toxins to specific cell targets. They are also being employed to create tumor vaccines by stimulating a host antibody reaction causing the production of anti-idiotype antibodies. 

Needle-free injectors have been developed to resolve the issue of pain and fear and hence to improve compliance. There are two types of needle-free injectors fluid and powder. Needle-free powder injectors have been utilized for the delivery of vaccines for hepatitis B, aprostadil for erectile dysfunction, the anesthetic lidocaine, a granulocyte-macrophage colony-stimulating factors tumor vaccine for malignant melanoma, and DNA-coated particles. 

Tarceva) and others Tumor Vaccines inhibitor inhibits cell proliferation signal transduction pathway headache, mucositis, hyperbilirubinemia, neutropenia, anemia ... 

A number of melanoma tumor vaccines have been evaluated in clinical trials in metastatic melanoma and in the adjuvant setting. The role of specific melanoma vaccines has not been defined at this time. 

Results from testing combinatorial libraries will support the design of cocktails of peptides applicable in prophylactic or therapeutic tumor vaccination or the construction of immunomodulating peptides for therapy of autoimmune diseases. Peptide libraries are also one of the most promising tools in the development of therapeutic approaches based on the actual status of an individuals immune response. 

Similarly, prostate cancer patients who relapsed after surgery or radiation therapy are being treated with the globo H tumor vaccine... 

Meng, W.S. and L.H. Butterfield. (2002) Rational design of peptide-based tumor vaccines. Pharm Res 19 926-932. 

PLASMID DNA-BASED ANTI-TUMOR VACCINES. One of the first reports of an antitumor pDNA-vaccine phase I trial used a dual expression plasmid coding HBS and carcino embryonic antigen (CEA), a protein overexpressed on many epithelial cancers. The plasmid was repetitively injected intramuscularly. Per injection, up to 2mg was applied. Some patients developed a good immune response toward HBS, but there was only a very limited response toward CEA. No objective clinical... 

---